Empowering Targeted Cancer Drug Discovery With Ai And Novel Disease Models, Signet Therapeutics Raises ~$10 Million In Seed-2 Round
Empowering Targeted Cancer Drug Discovery With Ai And Novel Disease Models, Signet Therapeutics Raises ~$10 Million In Seed-2 Round
10/29/21, 12:00 PM
Location
bostonMoney raised
$10 million
Round Type
seed
Signet Therapeutics, a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models, recently announced it has completed seed-2 round of approximately 10 million US dollars.
Company Info
Location
boston, massachusetts, united states
Additional Info
Signet Therapeutics is developing new medicines to meet the unmet medical need for the cancer patients, especially those insensitive to chemotherapy and radiotherapy.
By strategically collaborating with XtalPi, Signet brings together the expertise of an AI-powered drug discovery platform and unique novel disease models to discover and optimize promising new candidates for novel targeted cancer drugs. By taking these advantages, we hope to revolutionize traditional drug discovery for small molecules.